OxySure Therapeutics, Inc. - FORM 10-K - EX-32 - CERTIFICATION - March 31, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - OxySure Therapeutics, Inc.Financial_Report.xls
EX-10.29 - EXCLUSIVE DISTRIBUTION AGREEMENT - OxySure Therapeutics, Inc.f10k2014ex10xxix_oxysure.htm
EX-31.1 - CERTIFICATION - OxySure Therapeutics, Inc.f10k2014ex31i_oxysure.htm
EX-31.2 - CERTIFICATION - OxySure Therapeutics, Inc.f10k2014ex31ii_oxysure.htm
EX-23.2 - CONSENT - OxySure Therapeutics, Inc.f10k2014ex23ii_oxysure.htm
EX-10.2.3 - SECOND AMENDED AND RESTATED AGREEMENT - OxySure Therapeutics, Inc.f10k2014ex10ii3_oxysure.htm
EX-10.2.4 - SECOND RENEWED AND EXTENDED PROMISSORY NOTE - OxySure Therapeutics, Inc.f10k2014ex10ii4_oxysure.htm
EX-10.26 - SECURITIES PURCHASE AGREEMENT - OxySure Therapeutics, Inc.f10k2014ex10xxvi_oxysure.htm
EX-10.23.1 - AMENDMENT CERTIFICATE OF DESIGNATION - OxySure Therapeutics, Inc.f10k2014ex10xxiii1_oxysure.htm
10-K - ANNUAL REPORT - OxySure Therapeutics, Inc.f10k2014_oxysuresystem.htm
EX-10.27 - FORM OF WARRANT ISSUED TO SECURITIES PURCHASE AGREEMENT - OxySure Therapeutics, Inc.f10k2014ex10xxvii_oxysure.htm

Exhibit 32

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of OxySure Systems, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Julian T. Ross, Chief Executive Officer and Chief Financial Officer of the Company, respectively, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 31, 2015

 

/s/ Julian T. Ross  
Julian T. Ross  
Chief Executive Officer and Chief Financial Officer  

 

 

OxySure Therapeutics, Inc. Reports

Also read